Orthobiologics / Regenerative Medicine / Medical Devices
Strategic Profile
The company develops and sells injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing, with products focused on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. In 2024, Bonesupport Holding AB's revenue was 898.73 million SEK, an increase of 52.05% compared to the previous year.
Cyborg Score Rationale
Bonesupport demonstrates strong market fundamentals with robust revenue growth (52% YoY), established market position in orthobiologics, and a proven CERAMENT product platform. However, valuation metrics appear elevated relative to earnings, and governance scores show some concerns, restraining the score from exceptional.
Top Insights
52% revenue growth in 2024 demonstrates strong market acceptance and expansion momentum in orthobiologics
Dual-functioning products (CERAMENT G/V) combining bone regeneration with antibiotic delivery create competitive differentiation
Two-segment geography (North America and Europe & Rest of World) provides diversification and growth optionality
Recent 2026 pilot study publication for CERAMENT G in trauma signals clinical validation and market expansion potential
Named Competitors
Injectable bone graft substitutes — Competing orthobiologic solutions in trauma and orthopedic surgery
Traditional bone grafting solutions — Conventional alternatives to CERAMENT platform
Recent Developments
(February 2026) Published US Pilot Study results for CERAMENT G in trauma applications
(February 2026) Year-end 2025 report published with conference call and webcast
(2024) Achieved 52% revenue growth to 898.73 million SEK year-over-year
Open the full interactive Bonesupport Holding AB report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.